Latest Healthcare It News

IMEXHS Limited reported a 12% rise in annual recurring revenue to $36.8 million in 1H FY26, powered by its AI-enabled radiology platform now live in a public hospital network. Underlying EBITDA surged 311% to $1.27 million despite ongoing sector liquidity challenges in Colombia.

Australian Unity Limited (ASX:AYU) posted a statutory loss of $155.2 million for FY2026, reflecting regulatory headwinds, transformation costs, and sector disruptions, while advancing its climate risk management and strategic portfolio adjustments.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.

Optiscan Imaging has launched a 35-patient clinical trial in the US to test its InVue™ and InForm™ platforms in head and neck cancer surgery, aiming to bolster its FDA submissions later this year.

FOS Capital has kicked off orders under the Queensland Schools Lighting Upgrade Program, aiming to generate $2.5 million in sales over the next 6-9 months and boosting its secured order book to about $10 million.

Promisia Healthcare has cleared all material conditions for its $25 million acquisition of Chatswood Retirement Village in Christchurch, setting completion for 1 October 2026.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

AMCIL posted a $6.9 million profit for FY2026 while its portfolio returned negative 10%, underperforming the ASX 200. The company cut dividends to 4.0 cents fully franked, reshuffled holdings, and welcomed Alison Gibson as new CEO.

Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.

Novatti has swung to a positive EBITDA of $2.0 million in FY26, driven by strategic refocusing on its core Payments AU/NZ business despite a 40.7% revenue decline and loss of control over AUDC.

Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.